These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 217544)

  • 1. Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells.
    Thorley-Lawson DA
    Cell; 1979 Jan; 16(1):33-42. PubMed ID: 217544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polypeptides of the Epstein-Barr virus membrane antigen complex.
    Thorley-Lawson DA; Edson CM
    J Virol; 1979 Nov; 32(2):458-67. PubMed ID: 228070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
    Hoffman GJ; Lazarowitz SG; Hayward SD
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2979-83. PubMed ID: 6248876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences.
    Edson CM; Thorley-Lawson DA
    J Virol; 1981 Jul; 39(1):172-84. PubMed ID: 6268807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.
    Qualtiere LF; Chase R; Vroman B; Pearson GR
    Proc Natl Acad Sci U S A; 1982 Jan; 79(2):616-20. PubMed ID: 6176998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.
    Sairenji T; Bertoni G; Medveczky MM; Medveczky PG; Nguyen QV; Humphreys RE
    J Virol; 1988 Aug; 62(8):2614-21. PubMed ID: 2839689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus strain- and group-specific antigenic determinants detected by monoclonal antibodies.
    Mueller-Lantzsch N; Georg-Fries B; Herbst H; zur Hausen H; Braun DG
    Int J Cancer; 1981 Sep; 28(3):321-7. PubMed ID: 6172392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen.
    Kishishita M; Luka J; Vroman B; Poduslo JF; Pearson GR
    Virology; 1984 Mar; 133(2):363-75. PubMed ID: 6324457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.
    Thorley-Lawson DA; Geilinger K
    Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5307-11. PubMed ID: 6254073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of Epstein-Barr virus-related surface polypeptides expressed on n-butyrate-treated P3HR-1 cells.
    Kawanishi M; Sugawara K; Ito Y
    Intervirology; 1983; 19(3):162-8. PubMed ID: 6299996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel EBV-induced membrane glycoprotein of 43 kDa with H667 MAb.
    Sanchez-Pinel A; Bernad J; Rives H; Lapchine L; Icart J; Didier J
    Virology; 1991 Jan; 180(1):31-40. PubMed ID: 1845828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.
    Rowe M; Evans HS; Young LS; Hennessy K; Kieff E; Rickinson AB
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1575-86. PubMed ID: 2438376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid.
    Summers WC; Klein G
    J Virol; 1976 Apr; 18(1):151-5. PubMed ID: 176457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of an Epstein-Barr virus-associated membrane antigen component.
    North JR; Morgan AJ; Thompson JL; Epstein MA
    J Virol Methods; 1982 Sep; 5(1):55-65. PubMed ID: 6292251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
    Gerber P; Ablashi D; Magrath I; Armstrong G; Andersen P; Trach L
    J Natl Cancer Inst; 1982 Sep; 69(3):585-90. PubMed ID: 6287082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody specific for capsid antigen of Epstein-Barr virus.
    Takada K; Fujiwara S; Yano S; Osato T
    Med Microbiol Immunol; 1983; 171(4):225-31. PubMed ID: 6304479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A solid-phase radioimmunoassay for Epstein-Barr virus-associated membrane antigen prepared from B95-8 cell culture supernatants.
    Dölken G; Klein G
    J Natl Cancer Inst; 1977 May; 58(5):1239-45. PubMed ID: 192896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmune precipitation study comparing the Epstein-Barr virus membrane antigens expressed on P3HR-1 virus-superinfected Raji cells to those expressed on cells in a B-95 virus-transformed producer culture activated with tumor-promoting agent (TPA).
    Qualtiere LF; Pearson GR
    Virology; 1980 Apr; 102(2):360-9. PubMed ID: 6245514
    [No Abstract]   [Full Text] [Related]  

  • 19. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides.
    North JR; Morgan AJ; Epstein MA
    Int J Cancer; 1980 Aug; 26(2):231-40. PubMed ID: 6162806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demonstration of a surface antigen on Epstein-Barr virus genome-carrying lymphoid cells: distinction from the virus-determined membrane antigen.
    Sakamoto K; Hinuma Y
    J Immunol; 1978 May; 120(5):1702-8. PubMed ID: 207776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.